Drug Trial Radar · NCT06508658
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
379
Actual
Start
Aug 13, 2024
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world. Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
EpcoritamabDrug
Subcutaneous Injection
RituximabDrug
Intravenous (IV) Infusion
LenalidomideDrug
Oral Capsule
OxaliplatinDrug
IV Infusion
GemcitabineDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm A vs Arm B: Progression-Free Survival (PFS)Time frame: Up to 4 Years
Locations
176 sites in 28 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 273338
Duarte, California
Valkyrie Clinical Trials /ID# 269935
Los Angeles, California
Desert Regional Medical Center /ID# 272437
Palm Springs, California
Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823
Golden, Colorado
City Of Hope - Atlanta. /ID# 273092
Newnan, Georgia
Rush University Medical Center /ID# 242103
Chicago, Illinois
City Of Hope - Chicago /ID# 274430
Zion, Illinois
Northwest Cancer Center - Dyer Clinic /ID# 269787
Dyer, Indiana
Cancer Center of Kansas - Wichita /ID# 270117
Wichita, Kansas
University of Kentucky Chandler Medical Center. /ID# 242087
Lexington, Kentucky
University of Maryland, Baltimore /ID# 242216
Baltimore, Maryland
Henry Ford Hospital /ID# 266446
Detroit, Michigan
Gulfport Memorial Hospital /ID# 268104
Gulfport, Mississippi
New York Medical College /ID# 265799
Valhalla, New York
East Carolina University - Brody School of Medicine /ID# 242227
Greenville, North Carolina
Thompson Cancer Survival Ctr /ID# 242149
Knoxville, Tennessee
Community Cancer Trials Of Utah /ID# 271715
Ogden, Utah
Utah Cancer Specialists - Salt Lake City /ID# 268603
Salt Lake City, Utah
Veterans Affairs Medical Center - Salt Lake City /ID# 265329
Salt Lake City, Utah
Hospital Universitario Austral /ID# 242791
Pilar, Buenos Aires, Argentina
Fundaleu /Id# 242789
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
Instituto Alexander Fleming /ID# 263804
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
Canberra Hospital /ID# 265312
Garran, Australian Capital Territory, Australia
Royal Prince Alfred Hospital /ID# 263242
Sydney, New South Wales, Australia
Wollongong Hospital /ID# 244646
Wollongong, New South Wales, Australia
Toowoomba Hospital /ID# 263243
Toowoomba, Queensland, Australia
Monash Health - Monash Medical Centre /ID# 262783
Clayton, Victoria, Australia
Royal Perth Hospital /ID# 243790
Perth, Western Australia, Australia
Universitair Ziekenhuis Brussel /ID# 242574
Jette, Brussels Capital, Belgium
Centre Hospitalier Epicura - Hornu /ID# 265148
Boussu, Hainaut, Belgium
Universite Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 242565
Yvoir, Namur, Belgium
Universitair Ziekenhuis Leuven /ID# 246671
Leuven, Vlaams-Brabant, Belgium
AZ-Delta. /ID# 264740
Roeselare, West-Vlaanderen, Belgium
Hospital Alemao Oswaldo Cruz /ID# 247418
São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino - Regional Sao Paulo /ID# 263944
São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 242425
São Paulo, Brazil
Hospital Sao Rafael /ID# 262949
Salvador, Estado de Bahia, Brazil
Hospital Erasto Gaertner /ID# 264049
Curitiba, Puerto Rico, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto /ID# 264045
Ribeirão Preto, São Paulo, Brazil
UMHAT Sveti Georgi /ID# 242905
Plovdiv, Bulgaria
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.